Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04575961 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Study acronym: PERCEPTION
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Mar 1, 2026 to Feb 13, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 4 of 8 entries
    • Collaborators: details revised at 1 of 1 entry
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Apr 1, 2025 to Mar 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Nov 1, 2026 to Mar 1, 2028
    • Site details revised at 2 of 2 sites
    v7
  3. Primary completion date: Nov 1, 2024 to Apr 1, 2025v6
  4. Primary completion date: Nov 1, 2023 to Nov 1, 2024
    • Study completion date: Nov 1, 2025 to Nov 1, 2026
    v5
  5. Trial status: Not Yet Recruiting to Recruitingv4 Show 7 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 29 to 33
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 1, 2021 to Feb 22, 2022
    • Eligibility criteria expanded, about 50 words
    • Secondary endpoints revised (8)
    • Study description shortened, about 9 words
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Apr 1, 2021 to Dec 1, 2021v3
  2. Primary completion date: Nov 1, 2022 to Nov 1, 2023v2 Show 5 more changesShow less
    • Start date: Nov 1, 2020 to Apr 1, 2021
    • Primary endpoint revised
    • Study completion date: Nov 1, 2024 to Nov 1, 2025
    • Secondary endpoints: 7 to 8
    • Study title expanded, about 1 word
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin) administered concurrent to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma) having platinum-sensitive relapse (platinum-free interval \> 6 months).
Trial Details
NCT Number NCT04575961
Lead Sponsor North Eastern German Society of Gynaecological Oncology
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Related terms Cystadenocarcinoma, Serous, Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov